The landscape of advanced prostate cancer treatment has evolved tremendously in past decades. The treatment paradigm has shifted from androgen deprivation therapy (ADT) alone to doublet combinations comprising ADT with docetaxel or an androgen receptor inhibitor, and now triplet therapy involving all 3 classes of agents.
Robust clinical data has demonstrated survival benefits with this strategy of upfront treatment intensification. Subgroup analysis has alluded to the importance of tailoring treatment according to metastatic disease burden. However, defining the volume of disease is becoming increasingly controversial due to the advent of next generation molecular imaging. Several trials testing established agents in the castrate-resistant setting are now underway in metastatic hormone sensitive prostate cancer patients. As the treatment milieu is enriched earlier in the disease trajectory, future studies should elucidate biomarkers to further define specific patient populations who will benefit most from treatment intensification and/or de-escalation, with what agents and for what duration.
World journal of urology. 2022 Aug 27 [Epub ahead of print]
Kenneth Chen, Louise Kostos, Arun A Azad
Department of Urology, Singapore General Hospital, Singapore, Singapore., Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia., Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. .
PubMed http://www.ncbi.nlm.nih.gov/pubmed/36029329